Correction: Shrewsbury, S.B. The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and "Nose-to-Brain". Pharmaceutics 2023, 15 , 1720.

This document is a correction notice for an article discussing the delivery of drugs to the lower nasal space (LNS) and upper nasal space (UNS) and their potential benefits. It provides a list of various nasal delivery systems, including OptiNose's Xhance and Onzetra Xsail, which are approved for specific conditions. Other devices mentioned include Satsuma's STS101, AeroPump, PharmaSystems' Metered Nasal Dispenser, MeadWestvaco/Silgan's Mistette MkII Pump, Nemera's SP270+, SipNose, Teleflex's Mucosal Atomisation Device, BD's Accuspray, and Aptar's BiVax and LuerVax. The summary also mentions the target delivery areas and any limitations or issues associated with each device. This document is a valuable resource for library patrons researching nasal delivery systems. [Extracted from the article]